AntineoplasticsMyelosuppression, right lower extremity skin ulcerations secondary to off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1841卷 / 1期

关键词：

D O I：

10.1007/s40278-021-90536-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：34 / 34

相关论文

共 50 条

[1] KetoconazoleTroublesome pruritus and skin exfoliation secondary to off-label use: case report
Reactions Weekly, 2018, 1715 (1) : 153 - 153
[2] DexamethasoneAspergillosis secondary to off-label use: case report
Reactions Weekly, 2022, 1935 (1) : 177 - 177
[3] SpironolactoneHyperkalaemia secondary to off-label use: case report
Reactions Weekly, 2021, 1836 (1) : 710 - 710
[4] OsimertinibPneumonitis secondary to off-label use: case report
Reactions Weekly, 2020, 1814 (1) : 283 - 283
[5] AntineoplasticsMyelosuppression following off label use: case report
Reactions Weekly, 2021, 1844 (1) : 46 - 46
[6] Multiple drugsHypoglycaemia secondary to off-label use: case report
Reactions Weekly, 2020, 1816 (1) : 228 - 228
[7] TacrolimusBurning sensation secondary to off-label use: case report
Reactions Weekly, 2018, 1729 (1) : 251 - 251
[8] EmpagliflozinDiabetic ketoacidosis secondary to off-label use: case report
Reactions Weekly, 2019, 1756 (1) : 145 - 145
[9] ClopidogrelNose bleed secondary to off-label use: case report
Reactions Weekly, 2019, 1751 (1) : 106 - 106
[10] QuetiapinePancreatitis secondary to hypertriglyceridaemia and off-label use: case report
Reactions Weekly, 2018, 1720 (1) : 219 - 219

← 1 2 3 4 5 →